Ann Leen - Allovir Chief Officer
| ALVR Stock | USD 0.77 0.03 3.75% |
Insider
Ann Leen is Chief Officer of Allovir
| Age | 47 |
| Address | 1100 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 617 433 2605 |
| Web | https://www.allovir.com |
Allovir Management Efficiency
The company has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities. As of 10/19/2024, Return On Tangible Assets is likely to grow to -0.95. In addition to that, Return On Capital Employed is likely to drop to -1.17. At this time, Allovir's Total Assets are relatively stable compared to the past year. As of 10/19/2024, Other Current Assets is likely to grow to about 4.3 M, while Non Current Assets Total are likely to drop slightly above 3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dennis Mulroy | AnaptysBio | 69 | |
| David MD | 4D Molecular Therapeutics | 61 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Joshua Kazam | Kronos Bio | 47 | |
| Prof MD | Lyell Immunopharma | N/A | |
| BCh BM | Kronos Bio | 40 | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| JD Esq | 4D Molecular Therapeutics | 73 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| Jillian Connell | Merus BV | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Robert Fishman | 4D Molecular Therapeutics | 62 | |
| Dr DACVP | Agios Pharm | 63 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Marni Kottle | Kronos Bio | N/A | |
| Richard MD | Lyell Immunopharma | 72 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Cecilia Jones | Agios Pharm | 49 | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 |
Allovir Leadership Team
Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sonia Choi, Senior Relations | ||
| Agustin MD, Advisor | ||
| Dana MBA, VP Operations | ||
| Ann Leen, Chief Officer | ||
| Cintia PharmD, Chief Officer | ||
| David Hallal, Executive Board | ||
| Jeroen Beek, Consultant | ||
| Diana MD, CEO Director | ||
| Ugo Perlingieri, Head Operations | ||
| Brett Hagen, Chief Officer | ||
| Edward JD, General Secretary | ||
| Dana Alexander, Senior Operations |
Allovir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (31.42 M) | ||||
| Shares Outstanding | 115.36 M | ||||
| Shares Owned By Insiders | 49.21 % | ||||
| Shares Owned By Institutions | 42.99 % | ||||
| Number Of Shares Shorted | 5.5 M | ||||
| Price To Book | 0.74 X | ||||
| Gross Profit | 165 K | ||||
| EBITDA | (180.93 M) |
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving together with Allovir Stock
| 0.7 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Allovir Stock
| 0.66 | ERNA | Eterna Therapeutics | PairCorr |
| 0.62 | PTN | Palatin Technologies | PairCorr |
| 0.59 | DYAI | Dyadic International | PairCorr |
| 0.57 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | MBIO | Mustang Bio | PairCorr |
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.